

INFORMATION ONLY

Fibrinogen concentrate – no restrictions on brand mix

Customer Letter # 2021-29

2021-06-09

Dear Colleagues:

As an update to customer letters <u>2020-14</u> and <u>2020-43</u>, Canadian Blood Services is pleased to announce that supplies of fibrinogen concentrate (Fibryga® manufactured by Octapharma, and RiaStap® manufactured by CSL Behring) are such that customers may now order any brand for their patients.

There are no restrictions on the percentage of each brand that may be ordered.

Customers anticipating large shifts in their brand ordering practices are requested to contact their local Canadian Blood Services site in advance so that appropriate supply arrangements can be made to accommodate these shifts.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospitals Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier,

Director, Plasma Protein and Related Products Formulary Program